Eurofins Scientific (ERF) Stock Price, Fundamentals & Analysis

What ERF does

Eurofins Scientific (ERF) is a stock listed on the Euronext Paris stocks market in the Healthcare sector, specifically within the Diagnostics & Research industry. Headquartered in Luxembourg, Luxembourg, the company and its subsidiaries provide analytical testing and laboratory services worldwide. Its offerings span agroscience, consumer and human safety testing, environmental monitoring, biopharma services, and clinical diagnostics, as well as consumer product testing, cosmetics, and electrical and electronics laboratory services. With 65,000 employees, Eurofins Scientific operates a global network of laboratories.

Key numbers explained

• The current price is 77,36 EUR, reflecting the latest trading value of one share.
• The trailing P/E ratio of 26,9 indicates how much investors pay per euro of the company's last 12 months of earnings; a higher number can suggest higher growth expectations.
• The forward P/E ratio of 16,5 uses expected future earnings, offering a look at how the market values the company's upcoming profit potential.
• The dividend yield of 0,93% shows the annual dividend payment as a percentage of the share price, a measure of income return for shareholders.
• The ex-dividend date of 28 apr. 2026 is the cutoff date; buyers on or after this date do not receive the next dividend payment.
• The beta of 0,85 suggests the stock has historically been less volatile than the overall market.
• The 52-week price range of 54,86 – 79,22 EUR shows the lowest and highest traded prices over the past year, with the current price near the upper end of that band.
• The debt-to-equity ratio of 96,1% compares the company's total debt to its shareholder equity, indicating the level of financial leverage.

What to watch

For a stock like Eurofins Scientific, several general factors can influence its price. Revenue growth, reported at 2,5% year over year, reflects top-line expansion in a competitive diagnostics market. Profitability metrics such as the 7,2% profit margin and 16,2% operating margin show how efficiently the company converts sales into earnings. The 11,3% return on equity measures how effectively management uses shareholder capital. As a Healthcare stock, ERF can be affected by regulatory changes, funding for scientific research, and global demand for laboratory services. Investors often compare it with peers like Sanofi (SAN) and EssilorLuxottica (EL) to gauge sector performance. The next earnings report, scheduled for 23 iul. 2026, will provide updated insight into the company's financial trajectory.